AP
ORIC icon

Antipodes Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Antipodes Partners’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.2K Sell
1,278
-1,121
-47% -$12.7K ﹤0.01% 122
2025
Q4 		$19.6K Sell
2,399
-502
-17% -$5.78K ﹤0.01% 122
2025
Q3 		$34.8K Sell
2,901
-2,293
-44% -$24.1K ﹤0.01% 101
2025
Q2 		$52.7K Buy
5,194
+1,372
+36% +$9.21K ﹤0.01% 86
2025
Q1 		$21.3K Buy
+3,822
New +$33.4K ﹤0.01% 95

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Antipodes Partners's ORIC Position: Q1 2026 in Review

Antipodes Partners reduced its Oric Pharmaceuticals (ORIC) stake by 47% in Q1 2026, selling an estimated $12.7K and leaving 1,278 shares worth $16.2K. The position accounts for ﹤0.01% of the portfolio, ranked #122.

Antipodes Partners first reported a position in ORIC in Q1 2025 and has held it in 5 quarters since. The position peaked at $52.7K in Q2 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Antipodes Partners held 1,278 shares of Oric Pharmaceuticals worth $16.2K as of Q1 2026.
  • Antipodes Partners sold 1,121 Oric Pharmaceuticals shares in Q1 2026, an estimated $12.7K.
  • Oric Pharmaceuticals made up ﹤0.01% of Antipodes Partners's portfolio in Q1 2026, its #122 holding.
  • Antipodes Partners first reported a position in Oric Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Antipodes Partners's Oric Pharmaceuticals position peaked at $52.7K in Q2 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Antipodes Partners's 13F filing for Q1 2026, filed 5 May 2026.